4YD.F NANOLOGICA AB

Healthcare Biotechnology Frankfurt Exchange
0.0050 EUR
Close of Nov 11, 2026
0.0020 0.1250
Market cap
EUR 1.64M
P/E
0.2x
P/B
0.11x
ROE
59.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 4YD.F undervalued?

Graham number

The Graham number of NANOLOGICA AB cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

NANOLOGICA AB fundamental analysis

No fundamental analysis for NANOLOGICA AB yet.

NANOLOGICA AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About NANOLOGICA AB

Nanologica AB (publ), a life science tools company, develops, manufactures, and sells nanoporous silica particles in China, India, Turkey, the United States, and internationally. The company offers NLAB Saga, a silica-based purification media for preparative chromatography that is developed for the purification of peptide drugs, such as insulin and GLP-1 analogues; NLAB Idun, an ion exchange product for robust, reproducible, and efficient downstream purification of GLP-1 ana…

Full company profile